As China's first and the world's second approved IGF-1R antibody drug, SYCUME® has ended a 70-year drought of no new treatment option for TED in China. This groundbreaking therapy will redefine ...

Innovent Biologics (HKEX: 01801) has recently received approval for Sycume (teprotumumab biosimilar) to treat thyroid eye disease (TED) in China, making it the country’s first insulin-like growth ...

They conducted molecular dynamics simulations on the Ile91Leu variant and found it contributed to less stable binding affinity with the IGF-1 receptor (IGF-1R), thereby diminishing receptor ...

As China’s first and the world’s second approved IGF-1R antibody drug, Sycume has ended a 70-year drought of no new treatment option for thyroid eye disease in China. This groundbreaking therapy will ...

Researchers from Sanofi SA reported the preclinical characterization of SAR-446159 (ABL-301), a bispecific antibody construct comprising an antibody targeting α-synuclein fused to an engineered ...

We've already uncovered unique functions of VILPs including IGF-1 receptor inhibition. Furthermore, we're delving into the role of VILPs in host-pathogen interactions using the Grouper Iridovirus and ...

Innovent Biologics has announced the approval of SYCUME®, China’s first IGF-1R monoclonal antibody, by the National Medical Products Administration for treating thyroid eye disease (TED).